Non-invasive Testing for NASH and NASH with Advanced Fibrosis: Are We There Yet?
Nonalcoholic fatty liver disease (NAFLD) is the most prevalent etiology of chronic liver disease in America. NAFLD can be broadly classified in two subtypes: nonalcoholic fatty liver (NAFL), which is generally considered a benign condition with negligible risk of progression to cirrhosis, and nonalcoholic steatohepatitis (NASH), which is generally considered to be progressive with substantial risk of progression to cirrhosis. Additionally, recent studies suggest the odds of liver mortality increases amongst NASH patients with advanced fibrosis (bridging fibrosis ± cirrhosis). Liver biopsy examination is the current gold standard to accurately discriminate between NAFL vs. NASH as well as diagnose advanced fibrosis. However, due to its invasive nature, risk of bleeding (and even rarely death), prohibitive cost, and sampling error, liver biopsies are imperfect for diagnosis and monitoring of NAFLD. As a result, noninvasive biomarkers that can accurately detect NASH and advanced fibrosis without biopsy are needed. This article will discuss the most novel noninvasive biomarkers in diagnosing NASH and advanced fibrosis.
NAFLD Translational Research Unit, Division of Gastroenterology, Department of Medicine.
Ahilan
A
Arulanandan
NAFLD Translational Research Unit, Division of Gastroenterology, Department of Medicine ; Division of Epidemiology, Department of Family and Preventive Medicine, Department of Medicine.
Rohit
R
Loomba
advanced fibrosis; nonalcoholic fatty liver disease; nonalcoholic steatohepatitis; noninvasive biomarker